---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Incidence"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Incidence. Topics: Bladder cancer new cases in the United States, 2026 estimate; Bladder cancer incidence rate, lifetime risk, and age at diagnosis; Share of bladder cancer diagnosed as non-muscle-invasive disease; Population funnel from bladder cancer to BCG-unresponsive high-risk NMIBC, SEER and SEER-Medicare inputs; 4 further topics. 8 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/incidence"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of BCG-unresponsive high-risk non-muscle-invasive bladder cancer

<a id="topic-2.2.1.2.1-1"></a>

### Bladder cancer new cases in the United States, 2026 estimate

> “In 2026, an estimated 84,530 new cases of bladder cancer will be diagnosed in the US and 17,870 people will die from the disease”
> “Bladder is the only cancer for which in situ disease (diagnosed before it has spread beyond the layer of cells where it developed) is included in the case estimate because of its high likelihood of progression and recurrence.”
> “The incidence of bladder cancer is 4 times higher in men than in women.”
> “Bladder cancer incidence decreased by about 1% per year in both men and women from 2013 through 2022.”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.2.1-2"></a>

### Bladder cancer incidence rate, lifetime risk, and age at diagnosis

> “In 2026, it is estimated that there will be 84,530 new cases of bladder cancer and an estimated 17,870 people will die of this disease.”
> “The rate of new cases of bladder cancer was 17.9 per 100,000 men and women per year.”
> “Approximately 2.1 percent of men and women will be diagnosed with bladder cancer at some point during their lifetime, based on 2021–2023 data.”
> “Bladder cancer is most frequently diagnosed among people aged 65–74.”
> “Median Age At Diagnosis 73”

Source: [SEER Cancer Stat Facts Bladder Cancer (2026)](https://seer.cancer.gov/statfacts/html/urinb.html)

<a id="topic-2.2.1.2.1-3"></a>

### Share of bladder cancer diagnosed as non-muscle-invasive disease

> “Most patients (74%) are diagnosed with non–muscle-invasive bladder cancer (NMIBC),”

Source: [Gore et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12707586/)

> “At diagnosis, approximately three-quarters of bladder cancer cases present as non–muscle-invasive bladder cancer (NMIBC)”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-2.2.1.2.1-4"></a>

### Population funnel from bladder cancer to BCG-unresponsive high-risk NMIBC, SEER and SEER-Medicare inputs

> “Specifically, the prevalence of bladder cancer was 0.0634% and the incidence was 0.0244%, based on US Surveillance, Epidemiology, and End Results Program (SEER) registry data”
> “a real-world study of treatment patterns and clinical outcomes of US patients with bladder cancer based on the SEER-Medicare claims data, 73.1% of all patients with bladder cancer had NMIBC and, among them, 42.3% were classified as high-risk; 16.5% of patients with high-risk NMIBC had CIS ± Ta/T1 while 83.5% had high-grade Ta/T1 only”
> “Among patients with high-risk NMIBC, 56.5% were treated with BCG”
> “and 30% of those were unresponsive to BCG”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-2.2.1.2.1-5"></a>

### Population funnel assumptions in the ICER review: NMIBC stage mix and BCG non-response

> “Kirkali et al. estimated that approximately 70% of bladder cancers present as NMIBC, with approximately 70% classified as Ta, 20% as T1, and 10% as CIS”
> “we assumed that approximately 38% will be classified as BCG non-responders”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-2.2.1.2.1-6"></a>

### Proportion of high-risk NMIBC that fails BCG

> “However, more than 40% of patients with high-risk NMIBC do not respond to initial BCG treatment, and many experience loss of response over time”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

> “Unfortunately, initial BCG therapy fails in approximately 40% of patients over a 2-year span”

Source: [Steinberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4927860/)

> “High‐risk non‐muscle‐invasive bladder cancer (NMIBC) recurs after adequate intravesical BCG therapy in ~40% of patients”

Source: [Taylor et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745998/)

<a id="topic-2.2.1.2.1-7"></a>

### BCG-unresponsive share among recurrences after BCG, US electronic health record and claims cohort

> “The study included 26 876 patients with NMIBC (median [IQR] age at BCG initiation, 73 [65-77] years; 79.5% male), including 9639 patients with carcinoma in situ”
> “Of 5271 patients with carcinoma in situ–containing tumors and sufficient follow-up, 3134 (59.3%) experienced recurrence within 24 months, of whom 2604 (83.1%) were BCG exposed and 530 (16.9%) were BCG unresponsive.”

Source: [Giatsoglou et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087816/)

<a id="topic-2.2.1.2.1-8"></a>

### BCG-unresponsive share among classifiable BCG-treated high-grade NMIBC, single-center cohort

> “We conducted a retrospective cohort study for adults with histologically confirmed high-grade NMIBC treated with intravesical BCG at Moffitt Cancer Center between 1988 and 2024.”
> “Of 1076 NMIBC patients treated with BCG, 470 were classifiable: 245 (52.1%) were BCG-E, of whom 173 (70.6%) were resistant and 72 (29.4%) experienced delayed relapse, and 225 (47.9%) were BCG-UR.”

Source: [Jazayeri et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41421932/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
